OPTUS Pharmaceutical Co. Ltd.

As of March 31, 2026, OPTUS Pharmaceutical Co. Ltd. carries a market capitalization of 234.35B, placing it among publicly traded companies globally. Its enterprise value stands at 201.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, OPTUS Pharmaceutical Co. Ltd. has 17.37M shares outstanding.

As of March 31, 2026, OPTUS Pharmaceutical Co. Ltd. trades at a trailing price-to-earnings ratio of 16.83. The price-to-sales ratio is 2.33, and the price-to-book ratio stands at 1.33.

As of March 31, 2026, OPTUS Pharmaceutical Co. Ltd. trades at an EV/EBITDA multiple of 12.76 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.51 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 201.02B versus a market cap of 234.35B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, OPTUS Pharmaceutical Co. Ltd. maintains a current ratio of 3.28, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.78, indicating moderate leverage, while an interest coverage ratio of 231.52 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, OPTUS Pharmaceutical Co. Ltd. posted a return on equity (ROE) of 7.91, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.60 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.09, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.88, useful for judging operating efficiency across full business cycles. The company generates approximately 374.74M in revenue per employee across its workforce of 244.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.93 indicates how many times OPTUS Pharmaceutical Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, OPTUS Pharmaceutical Co. Ltd. recorded 110.81M in income tax expense. That works out to an effective tax rate of 0.87, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 12.81B, leaving 12.70B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, OPTUS Pharmaceutical Co. Ltd.'s stock has declined approximately 14.41% over the past 52 weeks. The 50-day moving average sits at 5,908.60, while the 200-day moving average is 7,626.98.

Over the twelve months ended March 31, 2026, OPTUS Pharmaceutical Co. Ltd. generated 91.62B in revenue and converted that into 12.70B in net income, yielding earnings per share of 801.71. EBITDA reached 15.75B, while operating income came in at 10.86B.

As of March 31, 2026, OPTUS Pharmaceutical Co. Ltd. holds 34.70B in cash and equivalents against 1.38B in total debt, resulting in a net debt position of -16.51B. Total book value stands at 176.05B, with working capital of 47.93B providing operational flexibility.

OPTUS Pharmaceutical Co. Ltd. produced 13.32B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -50.22B in capital expenditures, free cash flow totaled -36.91B - equivalent to -2,330.57 per share.

Over the twelve months ended March 31, 2026, OPTUS Pharmaceutical Co. Ltd. posted a gross margin of 55.47, reflecting its pricing power and cost economics. The operating margin of 11.85 and net profit margin of 13.86 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -17.28: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.21, meaning OPTUS Pharmaceutical Co. Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, OPTUS Pharmaceutical Co. Ltd. has an Altman Z-Score of 8.38, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.